Novo Nordisk launched the oral formulation of Wegovy in the U.S., listing insured patient copays as low as $25 per month and a $149 cash price. The company positioned the pill to broaden access to GLP‑1 therapy for obesity outside injectable formats. The Peterson Health Technology Institute issued five recommendations for employers managing GLP‑1 coverage, highlighting sustainability concerns, benefit design, and cost‑management strategies. The twin items frame an industry moment where rapid product launches meet payer and employer pressure to control spending and access.